首页> 美国卫生研究院文献>Cell Death Disease >A combination of cilostazol and Ginkgo biloba extract protects against cisplatin-induced Cochleo-vestibular dysfunction by inhibiting the mitochondrial apoptotic and ERK pathways
【2h】

A combination of cilostazol and Ginkgo biloba extract protects against cisplatin-induced Cochleo-vestibular dysfunction by inhibiting the mitochondrial apoptotic and ERK pathways

机译:西洛他唑和银杏叶提取物的组合可通过抑制线粒体凋亡和ERK途径来保护顺铂诱导的耳蜗前庭功能障碍。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cisplatin (cis-diammine-dichloroplatinum; CDDP) is an anticancer drug that induces significant hearing loss and balance dysfunction as side effects. Cilostazol (CS, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3, 4-dihydro-2-(1H)-quinolinone) has neuroprotective and antioxidant effects, whereas Ginkgo biloba extract (GbE) has preventive effects on CDDP-induced hearing loss in rats, and GbE enhances the antiatherogenic effect of CS by inhibiting the generation of reactive oxygen species (ROS). The purpose of this study was to investigate the effects of renexin (RXN), which contains GbE and CS, against CDDP-induced cochleo-vestibular dysfunction in rats and to elucidate the mechanism underlying the protective effects of RXN on auditory cells. Rats intraperitoneally injected with CDDP exhibited an increase in hearing threshold and vestibular dysfunction, which agreed with hair cell damage in the Organ of Corti and otoliths. However, these impairments were significantly prevented in a dose-dependent manner by pre- and co-treatment with RXN, and these preventive effects in RXN-treated rats were more prominent than those in GbE-treated rats. In a CDDP pharmacokinetic study, platinum concentration was very similar between CDDP-only treated and RXN+CDDP cotreated rats. RXN markedly attenuated CDDP-induced intracellular ROS and significantly reduced CDDP-activated expression of p-extracellular regulated kinase (ERK), BAX, cytochrome c, cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase, but increased BCL-XL expression. These results show that RXN may have a synergistic effect by strongly protecting hearing and vestibular dysfunction induced by CDDP by inhibiting ROS production, mitochondrial pathways and the ERK pathway, without interfering with CDDP pharmacokinetics. Therefore, RXN could potentially be used to reduce CDDP-related hearing loss and dizziness.
机译:顺铂(cis-diammine-dichloroplatinum; CDDP)是一种抗癌药,可引起严重的听力损失,并平衡副作用的功能障碍。西洛他唑(CS,6- [4-(1-(环环己基-1H-四唑-5-基)丁氧基] -3,4-二氢-2-(1H)-喹啉酮)具有神经保护和抗氧化作用,而银杏叶提取物( GbE对CDDP诱导的大鼠听力损失具有预防作用,并且GbE通过抑制活性氧(ROS)的产生增强CS的抗动脉粥样硬化作用。这项研究的目的是研究包含GbE和CS的肾上腺素(RXN)对CDDP诱导的大鼠耳蜗前庭功能障碍的影响,并阐明RXN对听觉细胞保护作用的机制。腹膜内注射CDDP的大鼠表现出听力阈值和前庭功能障碍的增加,这与Corti和耳石器官中的毛细胞损伤相吻合。但是,通过与RXN的预治疗和共治疗,这些损伤以剂量依赖的方式得到了显着的预防,并且在RXN治疗的大鼠中,这些预防作用比GbE治疗的大鼠中更为明显。在CDDP药代动力学研究中,仅CDDP处理的大鼠和RXN + CDDP共处理的大鼠的铂浓度非常相似。 RXN显着减弱CDDP诱导的细胞内ROS并显着降低p-细胞外调节激酶(ERK),BAX,细胞色素c,裂解的caspase-3和裂解的多聚(ADP-核糖)聚合酶的CDDP激活表达,但增加BCL-XL的表达。这些结果表明,在不干扰CDDP药代动力学的情况下,RXN可能通过抑制ROS的产生,线粒体途径和ERK途径,强力保护CDDP引起的听力和前庭功能障碍而具有协同作用。因此,RXN可能会用于减少CDDP相关的听力损失和头晕。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号